GILEAD SCIENCES, INC.

Average Profitability
<0.0001%
Insider Buys Quantity
6
Insider Buys Sum
$571.16M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of GILEAD SCIENCES, INC.

According to the SEC Form 4 filings, GILEAD SCIENCES, INC., being in a position of

  1. 10 percent owner at Arcus Biosciences, Inc.,
    оver the last 12 months, has bought 15238095 shares for $320M, and sold 0 shares,
    over all time since 2021-01-31, has bought 21898095 shares for $559.8M, and sold 0 shares.

The largest purchase of all time was on 2024-01-29 and amounted to 15238095 shares of Arcus Biosciences, Inc. for $320M.

Biography of GILEAD SCIENCES, INC.

No biography is available at this moment.

2024-06-17PurchaseAssembly Biosciences, Inc.
ASMB
10 percent owner
179,500
0.0002%
$0.00$180+3.86%
2024-04-02PurchaseXilio Therapeutics, Inc.
XLO
10 percent owner
485,250
0.9047%
$0.76$368,790-35.21%
2024-01-29PurchaseArcus Biosciences, Inc.
RCUS
10 percent owner
15.24M
28.0689%
$21.00$320M+7.64%
2023-06-28PurchaseArcus Biosciences, Inc.
RCUS
10 percent owner
1.01M
1.3257%
$19.26$19.45M-15.57%
2023-06-27PurchaseAlloVir, Inc.
ALVR
10 percent owner
2.93M
3.6696%
$3.75$10.99M-74.7%
2021-01-31PurchaseArcus Biosciences, Inc.
RCUS
10 percent owner
5.65M
9.458%
$39.00$220.35M
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.